Moderna Clinical Trials: 111 Led Studies

Archive historyOct 2022 to Jun 2026

235 recorded changes across Moderna trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 44 of these trials. One is shown below.

Status changeStatus moved to completed from active not recruitingNCT07117487 · recorded 1 Jun 2026

Track to read them

+231 more recorded changes · Track a drug to see every change the night it lands

Track pembrolizumab

Most active programmes

The drugs appearing most often across Moderna's recently active trials. Comparator arms are excluded.

mRNA-134513 trials
mRNA-127312 trials
mRNA-101012 trials
mRNA-16479 trials
mRNA-1273.2147 trials
Pembrolizumab4 trials

Upcoming readouts

Next primary completion dates among Moderna's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Jan 2027A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsPhase 3
Nov 2028A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme …Phase 2
Jan 2029A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placeb…Phase 2

Top therapeutic areas

Conditions studied most often across Moderna's recently active trials.

SARS-CoV-228 trials
Respiratory Syncytial Virus11 trials
Influenza11 trials
Seasonal Influenza8 trials
Cytomegalovirus Infection6 trials
COVID-195 trials

Moderna trials

The 50 most significant of Moderna's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk AdultsNCT06067230mRNA-1345	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	1,153 est.	30 Jul 2026
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.NCT05683457mRNA-1647	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	84 est.	1 Aug 2026
A Dose-finding Study to Evaluate mRNA-3210 in Participants With PhenylketonuriaNCT06147856mRNA-3210	Phase 1	Locked · track to reveal	StoppedWithdrawn	0 est.	10 Aug 2026
Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of AgeNCT05992935mRNA-1403	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	1,407 est.	22 Sept 2026
A Retrospective Study to Characterize Participants With Propionic AcidemiaNCT05769621	—	Not yet scored	OngoingRecruiting	60 est.	30 Sept 2026
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and AdultsNCT05164094mRNA-1189	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	867 est.	5 Oct 2026
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy ParticipantsNCT05831111mRNA-1195.1	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	482 est.	7 Oct 2026
A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)NCT05095727mRNA-3745	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	15 est.	30 Nov 2026
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsNCT06585241mRNA-1273 Variant-containing Formulation	Phase 4	Locked · track to reveal	OngoingRecruiting	1,144 est.	31 Dec 2026
A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy AdultsNCT07496450mRNA-1018-H5	Phase 3	Locked · track to reveal	OngoingRecruiting	4,000 est.	28 Jan 2027
A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and RecipientsNCT06133010mRNA-1647	Phase 2	Locked · track to reveal	StoppedWithdrawn	0 est.	14 Feb 2027
Nova 301A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute GastroenteritisNCT06592794mRNA-1403	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	37,864 est.	15 Feb 2027
A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189 in Healthy Adults 18 to 30 Years of AgeNCT07478952mRNA-1189	Phase 1	Locked · track to reveal	OngoingRecruiting	120 est.	15 May 2027
A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)NCT07266558mRNA-1273	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	30,000 est.	16 Jun 2027
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid TumorsNCT06880549mRNA-4106	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	42 est.	3 Aug 2027
Open-Label Study of mRNA-3927 in Participants With Propionic AcidemiaNCT04159103mRNA-3927	Phase 1	Locked · track to reveal	OngoingRecruiting	77 est.	31 Aug 2027
A Study to Assess Long-term Outcomes of Myocarditis Following Administration of COVID-19 mRNA Vaccine (SPIKEVAX)NCT06189053	—	Not yet scored	OngoingActive, not recruiting	1,500 est.	31 Oct 2027
KEYNOTE-603Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid TumorsNCT03313778mRNA-4157	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	161 est.	21 Nov 2027
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)NCT07561294mRNA-1982	Phase 2	Locked · track to reveal	OngoingRecruiting	350 est.	9 Nov 2028
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 YearsNCT06735248mRNA-1195	Phase 2	Locked · track to reveal	OngoingRecruiting	180 est.	8 Jan 2029
Post-marketing Surveillance (PMS) Use-Result Surveillance With SPIKEVAX BIVALENT, SPIKEVAX X Injection, SPIKEVAX JN Injection and SPIKEVAX IN PRE-FILLED SYRINGENCT06333704SPIKEVAX Bivalent BA.1	—	Not yet scored	OngoingActive, not recruiting	4,207 est.	29 Mar 2029
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 MonthsNCT05743881mRNA-1345	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	186 est.	31 Aug 2029
A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 StudyNCT05130437mRNA-3927	Phase 1	Locked · track to reveal	OngoingRecruiting	50 est.	4 Dec 2029
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple MyelomaNCT07116616mRNA-2808	Phase 1	Locked · track to reveal	OngoingRecruiting	166 est.	17 Jun 2030
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid TumorsNCT05533697mRNA-4359	Phase 1	Locked · track to reveal	OngoingRecruiting	361 est.	18 Feb 2032
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)NCT03897881mRNA-4157	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	267 est.	30 Nov 2032
An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705NCT05295433mRNA-3705	Phase 1	Locked · track to reveal	OngoingRecruiting	56 est.	2 Apr 2034
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of AgeNCT05701800mRNA-1468	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	659 est.	30 Jun 2026
A Study to Investigate Safety and Tolerability of mRNA-0184 Administered Subcutaneously in Healthy ParticipantsNCT06655870mRNA-0184	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	52 est.	23 Jun 2026
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing FormulationsNCT07089706mRNA-1283.251 Variant-containing Formulation	Phase 4	Locked · track to reveal	Completed	832 est.	16 Jun 2026
mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)NCT05918250mRNA-2736	Phase 1	Locked · track to reveal	StoppedWithdrawn	0 est.	27 May 2026
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus in Pregnant Women and in Infants Born to Vaccinated MothersNCT06143046mRNA-1345	Phase 2	Locked · track to reveal	Completed	360 est.	25 May 2026
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of AgeNCT05575492mRNA-1647	Phase 1	Locked · track to reveal	Completed	873 est.	12 May 2026
A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic AcidemiaNCT04899310mRNA-3705	Phase 1	Locked · track to reveal	StoppedTerminated	18 est.	1 Apr 2026
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of AgeNCT07117487mRNA-1345	Phase 3	Locked · track to reveal	Completed	507 est.	27 Mar 2026
A Study of Modified mRNA Vaccines in Healthy AdultsNCT05397223mRNA-1273	Phase 1	Locked · track to reveal	Completed	308 est.	27 Feb 2026
A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 VaccineNCT04975893mRNA-1647	Phase 2	Locked · track to reveal	Completed	135 est.	19 Jan 2026
Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of AgeNCT06694389mRNA-1083	Phase 3	Locked · track to reveal	Completed	2,457 est.	17 Nov 2025
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy AdultsNCT05606965mRNA-1010	Phase 2	Locked · track to reveal	Completed	172 est.	13 Nov 2025
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of AgeNCT05085366mRNA-1647	Phase 3	Locked · track to reveal	StoppedTerminated	7,454 est.	4 Nov 2025
A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of AgeNCT05436834mRNA-1273.214	Phase 3	Locked · track to reveal	Completed	1,807 est.	20 Oct 2025
A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of AgeNCT06864143mRNA-1083 Composition 1 Dose A Lot A	Phase 2	Locked · track to reveal	Completed	1,320 est.	13 Oct 2025
A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)NCT06508320mRNA-1083	Phase 2	Locked · track to reveal	Completed	932 est.	25 Sept 2025
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of AgeNCT06602024mRNA-1010	Phase 3	Locked · track to reveal	Completed	40,817 est.	21 Aug 2025
Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced MalignanciesNCT03739931mRNA-2752	Phase 1	Locked · track to reveal	Completed	134 est.	1 Aug 2025
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of AgeNCT05127434mRNA-1345	Phase 2	Locked · track to reveal	Completed	36,814 est.	28 Jul 2025
A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of AgeNCT05995275mRNA-1769	Phase 1	Locked · track to reveal	Completed	351 est.	8 Jul 2025
A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial VirusNCT06097299mRNA-1345	Phase 2	Locked · track to reveal	Completed	346 est.	27 Jun 2025
Study to Investigate Safety and Tolerability of mRNA-0184 Administered Under Different Infusion Conditions in Healthy ParticipantsNCT06243770mRNA-0184	Phase 1	Locked · track to reveal	Completed	44 est.	12 Jun 2025
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of AgeNCT05975099mRNA-1975	Phase 1	Locked · track to reveal	Completed	807 est.	30 May 2025

View all trials111

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

Phase 3Active, not recruitingNCT06067230 ↗

Primary completion: Jul 2026; estimated
Enrollment: 1,153; estimated
Start: Oct 2023; ModernaTX, Inc.

Conditions

Respiratory Syncytial Virus

Interventions

mRNA-1345

Brief summary

The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years. Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Sept 2025

Enrollment change · 1

Status change · 1

Completion date move · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Allogenic Hematopoietic Cell Transplantation (HCT) Participants.

Phase 2Active, not recruitingNCT05683457 ↗

Primary completion: Aug 2026; estimated
Enrollment: 84; estimated
Start: Apr 2023; ModernaTX, Inc.

Conditions

Cytomegalovirus Infection

Interventions

mRNA-1647
Placebo

Brief summary

The main purpose of the study is to evaluate the efficacy and safety of mRNA-1647 compared to placebo to prevent first clinically significant cytomegalovirus infection (CS-CMVi) in the period following cessation of CMV prophylactic treatment (for example, letermovir) on Day 100 post-HCT through Month 9 post-HCT.

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age

Phase 1Active, not recruitingNCT05992935 ↗

Primary completion: Sept 2026; estimated
Enrollment: 1,407; estimated
Start: Aug 2023; ModernaTX, Inc.

Conditions

Norovirus Acute Gastroenteritis

Interventions

mRNA-1403
mRNA-1405
Placebo

Brief summary

The purpose of the Part A Phase 1 of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adult participants 18 to 49 years of age and 60 to 80 years of age. The purpose of Part B Phase 2 and Part C Phase 2 is to evaluate the safety, reactogenicity, and…

Full record on ClinicalTrials.gov ↗

Change timeline

10 recorded · latest 1 May 2026

Completion date move · 4

Status change · 3

Enrollment change · 3

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

Phase 1Active, not recruitingNCT05164094 ↗

Primary completion: Oct 2026; estimated
Enrollment: 867; estimated
Start: Dec 2021; ModernaTX, Inc.

Conditions

Epstein-Barr Virus Infection

Interventions

mRNA-1189
Placebo

Brief summary

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main objective of Part B is to evaluate the safety and reactogenicity of mRNA-1189 in 12- to \<18-year-old healthy EBV-seronegative adolescents, and the main objective of Part…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Jul 2025

Status change · 3

Enrollment change · 3

Completion date move · 2

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations

Phase 4RecruitingNCT06585241 ↗

Primary completion: Dec 2026; estimated
Enrollment: 1,144; estimated
Start: Sept 2024; ModernaTX, Inc.

Conditions

SARS-CoV-2

Interventions

mRNA-1273 Variant-containing Formulation

Brief summary

The purpose of this study is to investigate the immunogenicity and safety of mRNA COVID-19 variant-containing vaccine formulations against the vaccine-matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Apr 2026

Completion date move · 3

Enrollment change · 2

Status change · 2

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Phase 2WithdrawnNCT06133010 ↗

Primary completion: Feb 2027; estimated
Enrollment: 0; estimated
Start: Feb 2024; ModernaTX, Inc.

Conditions

Cytomegalovirus Infection

Interventions

mRNA-1647
Placebo

Brief summary

The purpose of this study is to assess the effect of pre-transplant mRNA-1647 on post-transplant cytomegalovirus (CMV) virologic outcomes, anti-CMV antiviral use, and clinical outcomes in CMV-seropositive and CMV-seronegative liver transplant candidates who receive transplants and to assess the safety, reactogenicity,…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2024

Enrollment change · 1

Status change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

Nova 301: A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis

Phase 3Active, not recruitingNCT06592794 ↗

Primary completion: Feb 2027; estimated
Enrollment: 37,864; estimated
Start: Sept 2024; ModernaTX, Inc.

Conditions

Acute Gastroenteritis
Norovirus Acute Gastroenteritis

Interventions

mRNA-1403
Placebo

Brief summary

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Mar 2026

Status change · 4

Enrollment change · 2

Completion date move · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Phase 1Active, not recruitingNCT05743881 ↗

Primary completion: Aug 2029; estimated
Enrollment: 186; estimated
Start: Feb 2023; ModernaTX, Inc.

Conditions

Respiratory Syncytial Virus
Human Metapneumovirus

Interventions

mRNA-1345
mRNA-1365
Placebo
Nimenrix

Brief summary

The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Sept 2025

Status change · 3

Enrollment change · 2

Completion date move · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)

Phase 2Active, not recruitingNCT03897881 ↗

Primary completion: Nov 2032; estimated
Enrollment: 267; estimated
Start: Jul 2019; ModernaTX, Inc.

Conditions

Melanoma

Interventions

mRNA-4157
Pembrolizumab

Brief summary

The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Jan 2026

Completion date move · 3

Status change · 2

Enrollment change · 2

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

An Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3705 in Participants Previously Enrolled in Other Clinical Studies of mRNA-3705

Phase 1RecruitingNCT05295433 ↗

Primary completion: Apr 2034; estimated
Enrollment: 56; estimated
Start: Mar 2022; ModernaTX, Inc.

Conditions

Methylmalonic Acidemia

Interventions

mRNA-3705

Brief summary

The primary objective of this study is to evaluate the long-term safety and clinical activity of mRNA-3705 administered to participants with isolated methylmalonic acidemia (MMA) due to methylmalonyl-coenzyme A mutase (MUT) deficiency who have previously participated in other clinical studies of mRNA-3705.

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2026

Completion date move · 1

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Phase 1CompletedNCT05575492 ↗

Primary completion: May 2026; actual
Enrollment: 873; estimated
Start: Nov 2022; ModernaTX, Inc.

Conditions

Cytomegalovirus

Interventions

mRNA-1647
Placebo

Brief summary

The main purpose of study is to evaluate the safety and immunogenicity of different dose levels of mRNA-1647 versus control in healthy cytomegalovirus (CMV)-seronegative and CMV-seropositive female and male participants 9 to 15 years of age. In addition, mRNA-1647 will be evaluated in female participants 16 to 25…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Oct 2025

Status change · 3

Completion date move · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of mRNA-3705 in Participants With Isolated Methylmalonic Acidemia

Phase 1TerminatedNCT04899310 ↗

Primary completion: Apr 2026; actual
Enrollment: 18; estimated
Start: Aug 2021; ModernaTX, Inc.

Conditions

Methylmalonic Acidemia

Interventions

mRNA-3705
Placebo

Brief summary

This is a study of mRNA-3705 in participants with isolated elevated methylmalonic acid (MMA) due to methylmalonyl-coenzyme A (CoA) mutase (MUT) deficiency. The main goal of the study is to assess safety, efficacy, pharmacokinetics, and pharmacodynamics of intravenously (IV)-infused mRNA-3705.

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Jun 2026

Enrollment change · 3

Status change · 2

Completion date move · 2

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Phase 3CompletedNCT07117487 ↗

Primary completion: Mar 2026; actual
Enrollment: 507; estimated
Start: Aug 2025; ModernaTX, Inc.

Conditions

Respiratory Syncytial Virus

Interventions

mRNA-1345

Brief summary

The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

Phase 2CompletedNCT04975893 ↗

Primary completion: Jan 2026; actual
Enrollment: 135; estimated
Start: Jun 2021; ModernaTX, Inc.

Conditions

Cytomegalovirus Infection

Interventions

mRNA-1647
mRNA-1647

Brief summary

The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-seronegative and CMV-seropositive adults who completed Study mRNA-1647-P202 (NCT04232280). For participants in the optional booster phase (BP), the main purpose is to…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Mar 2026

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Phase 3CompletedNCT06694389 ↗

Primary completion: Nov 2025; actual
Enrollment: 2,457; estimated
Start: Nov 2024; ModernaTX, Inc.

Conditions

COVID-19
Influenza

Interventions

mRNA-1083
Placebo
Licensed Influenza Vaccine
SARS-CoV-2 Vaccine

Brief summary

The purpose of the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea).

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jan 2026

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Phase 2CompletedNCT05606965 ↗

Primary completion: Nov 2025; actual
Enrollment: 172; estimated
Start: Nov 2022; ModernaTX, Inc.

Conditions

Influenza

Interventions

mRNA-1010
Egg-based Quadrivalent Influenza Vaccine
Adjuvanted Quadrivalent Influenza Vaccine
Inactivated Influenza Vaccine
mRNA-1345
mRNA-1045

Brief summary

The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.

Full record on ClinicalTrials.gov ↗

Change timeline

16 recorded · latest 1 Dec 2025

Completion date move · 6

Status change · 5

Enrollment change · 5

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

Phase 3TerminatedNCT05085366 ↗

Primary completion: Nov 2025; actual
Enrollment: 7,454; estimated
Start: Oct 2021; ModernaTX, Inc.

Conditions

Cytomegalovirus Infection

Interventions

mRNA-1647
Placebo

Brief summary

The main purpose of this study is to evaluate the efficacy of mRNA 1647 vaccine in CMV-seronegative female participants and to evaluate the safety and reactogenicity of mRNA-1647 vaccine in all participants. The purpose of the Phase 3 extension substudy is to extend the observation period of the main study and to…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jan 2026

Status change · 2

Completion date move · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age

Phase 3CompletedNCT05436834 ↗

Primary completion: Oct 2025; actual
Enrollment: 1,807; estimated
Start: Jun 2022; ModernaTX, Inc.

Conditions

SARS-CoV-2

Interventions

mRNA-1273.214
mRNA-1273.815

Brief summary

This study will evaluate the safety and immunogenicity of the mRNA-1273.214 vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concerns (VOCs) in participants aged 6 months to \<6 years, when administered as a primary series in SARS-CoV-2 vaccine-naïve participants (Part 1) and a…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 Dec 2025

Enrollment change · 3

Completion date move · 3

Status change · 3

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (Influenza and COVID-19) Vaccine in Adults ≥18 to <65 Years of Age

Phase 2CompletedNCT06864143 ↗

Primary completion: Oct 2025; actual
Enrollment: 1,320; estimated
Start: Mar 2025; ModernaTX, Inc.

Conditions

Influenza
SARS-CoV-2

Interventions

mRNA-1083 Composition 1 Dose A Lot A
mRNA-1083 Composition 1 Dose A Lot B
mRNA-1083 Composition 1 Dose B
mRNA-1083 Composition 1 Dose C
mRNA-1083 Composition 2 Dose A
mRNA-1083 Composition 2 Dose B
mRNA-1083 Composition 3 Dose A
mRNA-1083 Composition 3 Dose B

Brief summary

The purpose of this study is to evaluate the immunogenicity, reactogenicity, and safety, of mRNA-1083 multicomponent influenza and COVID-19 vaccine in adults ≥18 to \<65 years of age.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Nov 2025

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)

Phase 2CompletedNCT06508320 ↗

Primary completion: Sept 2025; actual
Enrollment: 932; estimated
Start: Jul 2024; ModernaTX, Inc.

Conditions

Influenza
SARS-CoV-2

Interventions

mRNA-1083

Brief summary

The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Nov 2025

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age

Phase 3CompletedNCT06602024 ↗

Primary completion: Aug 2025; actual
Enrollment: 40,817; estimated
Start: Sept 2024; ModernaTX, Inc.

Conditions

Seasonal Influenza

Interventions

mRNA-1010
Fluarix®
Influsplit® Tetra
Fluarix Tetra
Alpharix® Tetra

Brief summary

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of mRNA-1010 versus an active comparator against reverse transcription polymerase chain reaction (RT-PCR)-confirmed protocol-defined influenza-like illness (ILI) caused by…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Oct 2025

Status change · 3

Completion date move · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Phase 1CompletedNCT03739931 ↗

Primary completion: Aug 2025; actual
Enrollment: 134; estimated
Start: Nov 2018; ModernaTX, Inc.

Conditions

Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma

Interventions

mRNA-2752
Durvalumab

Brief summary

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory solid tumor malignancies or lymphoma.

Full record on ClinicalTrials.gov ↗

Change timeline

7 recorded · latest 1 Sept 2025

Completion date move · 4

Status change · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

Phase 2CompletedNCT05127434 ↗

Primary completion: Jul 2025; actual
Enrollment: 36,814; estimated
Start: Nov 2021; ModernaTX, Inc.

Conditions

Respiratory Syncytial Virus

Interventions

Placebo
mRNA-1345

Brief summary

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single dose of mRNA-1345 vaccine in the prevention of a first episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Sept 2025

Completion date move · 2

Status change · 2

Enrollment change · 1

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Phase 2CompletedNCT06097299 ↗

Primary completion: Jun 2025; actual
Enrollment: 346; estimated
Start: Oct 2023; ModernaTX, Inc.

Conditions

Respiratory Syncytial Virus

Interventions

mRNA-1345
Placebo

Brief summary

Part A: The purpose is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1345 in children aged 2 to \<5 years (Cohort 1) and in children at high risk of respiratory syncytial virus (RSV) disease 5 to \<18 years of age (Cohort 2) to inform the dose level selection for the next phase of development…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Aug 2025

Completion date move · 3

Enrollment change · 3

Status change · 2

Track Moderna drugs to see every change the night it lands.

Track pembrolizumab